XTX Topco Ltd Has $523,000 Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

XTX Topco Ltd increased its position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 47.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 182,888 shares of the company’s stock after purchasing an additional 58,587 shares during the quarter. XTX Topco Ltd’s holdings in Poseida Therapeutics were worth $523,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fred Alger Management LLC acquired a new stake in Poseida Therapeutics in the third quarter valued at approximately $369,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Poseida Therapeutics by 62.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after purchasing an additional 138,510 shares during the period. Renaissance Technologies LLC increased its stake in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after purchasing an additional 297,500 shares in the last quarter. Advantage Alpha Capital Partners LP bought a new stake in Poseida Therapeutics during the 3rd quarter valued at $285,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Poseida Therapeutics by 9.4% in the second quarter. Acadian Asset Management LLC now owns 399,839 shares of the company’s stock valued at $1,165,000 after buying an additional 34,321 shares in the last quarter. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Stock Performance

Shares of PSTX opened at $9.51 on Friday. The stock has a 50 day moving average of $4.57 and a 200 day moving average of $3.54. The company has a market capitalization of $929.83 million, a price-to-earnings ratio of -15.10 and a beta of 1.64. Poseida Therapeutics, Inc. has a 12 month low of $1.87 and a 12 month high of $9.58. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68.

Wall Street Analyst Weigh In

Several research firms have recently commented on PSTX. HC Wainwright reissued a “neutral” rating and set a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Piper Sandler downgraded Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target for the company. in a report on Monday, December 2nd. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $9.50.

Insider Activity

In related news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the completion of the transaction, the chairman now owns 651,291 shares in the company, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.90% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.